Sandimmun Neoral-50mg (Ciclosporin Capsule) 50 MG

Sandimmun Neoral-50mg is indicated for several immune‑mediated conditions where suppression of T‑cell activity is required.

• Prevention of acute rejection in organ transplant recipients (kidney, liver, heart).
• Management of severe chronic plaque psoriasis unresponsive to conventional therapy.
• Treatment of severe rheumatoid arthritis when other disease‑modifying agents are insufficient (off‑label).
• Use in certain dermatologic disorders such as atopic dermatitis under specialist guidance.
• Adjunct therapy in selected autoimmune diseases as determined by a physician.

• Ciclosporin binds to the intracellular protein cyclophilin, forming a complex that inhibits the phosphatase activity of calcineurin. This inhibition blocks the dephosphorylation of nuclear factor of activated T‑cells (NFAT), preventing its translocation to the nucleus and thereby reducing interleukin‑2 (IL‑2) gene transcription. The downstream effect is a marked reduction in T‑cell activation and proliferation, leading to immunosuppression.

Side effects of Sandimmun Neoral-50mg vary in frequency and severity.

Common

• Headache
• Tremor or mild muscle twitching
• Hypertension
• Increased serum creatinine or reduced kidney function
• Gum hyperplasia or overgrowth
• Nausea or abdominal discomfort

Serious

• Severe nephrotoxicity leading to renal failure
• Opportunistic infections (e.g., cytomegalovirus, fungal)
• Malignancies such as lymphoma or skin cancer
• Hepatotoxicity with elevated liver enzymes
• Neurotoxicity presenting as seizures or encephalopathy
• Severe allergic reactions including Stevens‑Johnson syndrome

Patients should be evaluated carefully before starting Sandimmun Neoral-50mg and monitored throughout therapy.

• Baseline and periodic assessment of renal and hepatic function.
• Regular monitoring of blood pressure and serum electrolytes, especially potassium and magnesium.
• Screening for infections prior to initiation and vigilance for new infections during treatment.
• Avoid use in pregnancy unless benefits outweigh risks; discuss contraception with women of child‑bearing potential.
• Caution in patients with a history of malignancy, as immunosuppression may increase recurrence risk.
• Adjust dose in the presence of significant drug‑induced liver or kidney impairment.

Ciclosporin has a narrow therapeutic index and interacts with many medications.

Avoid

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) that can raise ciclosporin levels.
• Nephrotoxic agents such as aminoglycosides, amphotericin B, or high‑dose NSAIDs.
• Live vaccines, due to reduced immune response.

Use with caution

• Other immunosuppressants (e.g., azathioprine, mycophenolate) which may increase infection risk.
• Calcium channel blockers (e.g., diltiazem) that may modestly increase ciclosporin concentrations.
• Diuretics that can affect electrolyte balance and renal function.
• Antifungal agents with moderate CYP3A4 inhibition (e.g., fluconazole).